<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226405</url>
  </required_header>
  <id_info>
    <org_study_id>17-183</org_study_id>
    <nct_id>NCT03226405</nct_id>
  </id_info>
  <brief_title>Patient Navigation to Improve Patient-Centered Cancer Care</brief_title>
  <official_title>Patient Navigation to Improve Patient-Centered Cancer Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MGH Cancer Center's patient navigation (PN) program, utilizes specially trained
      community-based personnel to improve cancer care in underserved communities by increasing
      cancer screening and removing barriers to timely care. This program incorporate rigorous
      evaluation to demonstrate the impact of innovation in healthcare delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This program allow cancer patients from MGH Community Health Centers (CHC) and surrounding
      communities who experience barriers to accessing care, including poverty, and limited English
      proficiency, and provide them navigation to receive timely, guideline-concordant treatment at
      MGH Cancer Center. By offering these vulnerable individuals a patient-centered approach to
      treatment, The investigators aim to promote patient engagement and increase access throughout
      the continuum of cancer care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">October 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence With Cancer Treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Adherence with cancer treatment will be measured as no-show rate to scheduled oncology appointments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Time From Cancer Diagnosis To First Oncology Appointment</measure>
    <time_frame>2 Years</time_frame>
    <description>Length of time in days from cancer diagnosis to first completed oncology appointment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality Of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Health related quality of life measured via the validated Functional Assessment of Cancer Therapy - General (FACT-G).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival rate of the study population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion Of Patients Enrolled In Clinical Trials</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of participants in the study that enroll on a clinical trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Missed Health Care Visits</measure>
    <time_frame>2 years</time_frame>
    <description>Number of scheduled health care visits missed by enrolled patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency Department Visits</measure>
    <time_frame>2 years</time_frame>
    <description>Number of emergency department visits by enrolled patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned Hospitalizations/Readmissions</measure>
    <time_frame>2 years</time_frame>
    <description>Number of unplanned hospitalizations and/or readmissions by enrolled patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inpatient Hospitalization Length Of Stay.</measure>
    <time_frame>2 years</time_frame>
    <description>Number of days enrolled patients spent as a hospitalized inpatient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With Patient Navigation Program (PNP)</measure>
    <time_frame>2 years</time_frame>
    <description>Patient satisfaction with patient navigation program (PNP) to be measured via the validated Patient Satisfaction with Navigation - 1 (PSN-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Engagement In Care</measure>
    <time_frame>2 years</time_frame>
    <description>Patient engagement in care will be measured using the validated Perceived Efficacy in Patient-Physician Interactions (PEPPI) metric.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Financial Burden</measure>
    <time_frame>2 years</time_frame>
    <description>Patient financial burden will be measured using the validated Comprehensive Score for Financial Toxicity (COST) instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction with Cancer Care</measure>
    <time_frame>2 years</time_frame>
    <description>Patient satisfaction with cancer care to be measured using the validated Cancer-Related Care Survey.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Patient Navigation Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study team will identify, track, and provide navigation for all adult patients referred to Cancer Center from the CHC and community partners for cancer treatment.
The Patient Navigation Program include
Education,
Appointment reminders,
Help with insurance,
Transportation,
Navigating the Cancer Center,
Assisting in finding appropriate child care,
Interpreting,
Connecting the patient to psychosocial and/or palliative care teams,
Physically escorting the patient to appointments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will receive enhanced usual care,
This consist of personal phone call reminders about upcoming appointments at the MGH Cancer Center</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Navigation Program</intervention_name>
    <description>PN program improve access, timeliness and adherence with cancer treatment</description>
    <arm_group_label>Patient Navigation Program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>the standard of care provided by the institution</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age 18 and older)

          -  Newly diagnosed with cancer referred from Massachusetts General Hospital (MGH)
             community health centers in

               -  Revere

               -  Chelsea

               -  Charlestown

               -  surrounding communities referred to receive cancer treatment at the MGH Cancer
                  Center

        Exclusion Criteria:

        -Patients that primary care providers exclude
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanja Percac-Lima, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Gorton</last_name>
    <phone>617-643-5970</phone>
    <email>egorton@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Gorton</last_name>
      <phone>617-643-5970</phone>
      <email>egorton@partners.org</email>
    </contact>
    <investigator>
      <last_name>Sanja Percac-Lima, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Sanja Percac-Lima, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

